Kofarest-PD Drop is a combination pharmaceutical formulation containing Ambroxol (7.5 mg/ml), Levosalbutamol (0.25 mg/ml), and Guaifenesin (12.5 mg/ml), designed for the symptomatic treatment of respiratory tract disorders associated with excessive mucus production and bronchospasm. Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of viscous bronchial secretions, thereby improving expectoration. Levosalbutamol, a selective β2-adrenergic receptor agonist, provides bronchodilation by relaxing bronchial smooth muscle, which helps alleviate bronchospasm and improve airflow. Guaifenesin serves as an expectorant, promoting the hydration of respiratory tract secretions and enhancing mucus clearance. The synergistic action of these components makes Kofarest-PD Drop effective in managing conditions such as acute and chronic bronchitis, asthma exacerbations, and other obstructive airway diseases where mucus hypersecretion and bronchoconstriction are prominent. This formulation is typically administered orally in pediatric and adult patients, with dosage adjusted according to clinical severity and patient age. It is important to use Kofarest-PD Drop under medical supervision, particularly in patients with cardiovascular disorders, hypertension, or hypersensitivity to any of the active ingredients. Adverse effects may include mild gastrointestinal discomfort, tremors, or allergic reactions, warranting prompt medical consultation if they occur.